Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Castration Resistant Prostate Cancer
95%
Prognostication
71%
Urokinase Receptor
71%
Bone Scintigraphy
56%
Fluorodeoxyglucose F 18
55%
Computer Assisted Tomography
53%
Pediatrics
47%
Magnetic Resonance Imaging
45%
Positron Emission Tomography
42%
Diagnosis
40%
Bone Metastasis
35%
Radioactive Tracer
35%
Overall Survival
35%
Conventional Imaging
33%
Positron Emission Tomography
31%
Fluorine-18
31%
Radium Chloride Ra 223
27%
Technetium-99
27%
Positron Emission Tomography - Magnetic Resonance Imaging
26%
Gleason Score
23%
Systematic Review
23%
Inappropriate Vasopressin Secretion
23%
Bone Cancer
23%
Head and Neck Cancer
23%
Ganglioneuroblastoma
23%
Clinical Trial
23%
Magnetic Resonance Imaging of Prostate
23%
Prostate Cancer
23%
Lung Tuberculosis
23%
Liquid Biopsy
23%
Chest Radiograph
23%
General Anesthesia
23%
Bone Density
23%
Therapy Delay
23%
Eosinophilic
23%
Alginic Acid
23%
Rhabdomyosarcoma
23%
Dual-Energy X-Ray Absorptiometry
23%
Cystic Fibrosis
23%
Cystitis
23%
Placebo
23%
Oligosaccharide
23%
Diabetic Foot
23%
Nasal Glioma
23%
Osteoarthropathy
23%
Copper 64
23%
Infective Endocarditis
23%
Iodine 123
21%
Scintigraphy
19%
Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
74%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
71%
Radium-223 Therapy
53%
Positron Emission Tomography-computed Tomography (PET-CT)
52%
Radium-223
51%
Magnetic Resonance Imaging
39%
Imaging Modalities
36%
Pediatric
35%
Bone Metastasis
34%
Conventional Imaging
33%
Body Composition
31%
Dual-energy X-ray Absorptiometry
31%
Computed Tomography
31%
Prostate Cancer Patients
30%
Response Assessment
30%
Clinical Outcomes
30%
Overall Survival
29%
SUVmax
29%
PET-MRI
27%
Prospective Phase II Study
23%
Post-therapeutic
23%
Positron Emission tomography-CT
23%
Head-and-neck Cancer
23%
18F-MFBG
23%
Cancer Patients
23%
Liquid Biopsy
23%
Skeletal Tumor Burden
23%
PET-computed Tomography
23%
Conversion Rate
23%
Sedation Anesthesia
23%
Alginate Oligosaccharides
23%
Aggressiveness
23%
Long Axial Field of View PET
23%
Bone Mineral Density
23%
Body Composition Assessment
23%
Neuroblastoma
23%
Technetium-99m
23%
General Anesthesia
23%
Castration-resistant Prostate Cancer
23%
Treatment Impact
23%
Pediatric Rhabdomyosarcoma
23%
Three-phase Bone Scintigraphy
23%
Eosinophilic Cytoplasm
23%
Imaging Response
23%
Tuberculosis in children
23%
Inhaled Dry Powder
23%
Placebo-controlled
23%
Treatment Delay
23%
SIADH
23%
Pulmonary Tuberculosis
23%
